DDD Partners LLC Sells 357,039 Shares of Genmab A/S (NASDAQ:GMAB)

DDD Partners LLC decreased its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 61.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 226,074 shares of the company's stock after selling 357,039 shares during the period. DDD Partners LLC's holdings in Genmab A/S were worth $4,718,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GMAB. GAMMA Investing LLC boosted its holdings in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. R Squared Ltd bought a new position in Genmab A/S in the fourth quarter valued at about $93,000. Blue Trust Inc. boosted its holdings in Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after acquiring an additional 3,880 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock valued at $113,000 after acquiring an additional 1,413 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after buying an additional 827 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. BMO Capital Markets restated an "outperform" rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Stock Performance

Genmab A/S stock traded up $0.47 during midday trading on Thursday, reaching $22.44. The stock had a trading volume of 1,030,401 shares, compared to its average volume of 1,581,458. The firm's fifty day simple moving average is $20.64 and its 200-day simple moving average is $22.97. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.88. The stock has a market capitalization of $14.85 billion, a P/E ratio of 12.90, a price-to-earnings-growth ratio of 2.57 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.